Stockscreener 앱 받기
2.03
1.50%
0.03
전일 마감가:
$2.00
열려 있는:
$2.06
하루 거래량:
5.85M
Relative Volume:
1.28
시가총액:
$319.81M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-101.50
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
+118.66%
1개월 성능:
+222.38%
6개월 성능:
+123.08%
1년 성능:
+1.50%
1일 변동 폭
$1.9502
$2.16
1주일 범위
$1.65
$2.55
52주 변동 폭
$0.40
$2.55
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.03 | 74.85M | 101.21M | -569.00K | -56.88M | -0.02 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
CytomX upgraded at H.C. Wainwright on trial data for cancer drug - MSN
CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler | CTMX Stock News - GuruFocus
After pivots and layoffs, CytomX Therapeutics smells success, $100 million payoff - The Business Journals
CytomX stock upgraded at H.C. Wainwright (CTMX:NASDAQ) - Seeking Alpha
H.C. Wainwright raises CytomX stock to buy, target to $5.00 By Investing.com - Investing.com India
HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - Nasdaq
CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX - GuruFocus
CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX Stock News - GuruFocus
HC Wainwright Upgrades CytomX Therapeutics to Buy From Neutral, Price Target is $5 - marketscreener.com
CytomX Therapeutics (CTMX) Price Target Doubled Following Promis - GuruFocus
CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX St - GuruFocus
CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX Stock News - GuruFocus
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates - MSN
Institutional investors have a lot riding on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with 52% ownership - simplywall.st
CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials - Value The Markets
CytomX Therapeutics Secures $93.4 Million Through Stock Sale - TipRanks
CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? - Seeking Alpha
CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering - MSN
CytomX (CTMX) Exceeds Revenue Expectations and Advances CRC Drug Development | CTMX Stock News - GuruFocus
CytomX Therapeutics Reports Q1 2025 Results and Progress - TipRanks
CytomX Therapeutics: Q1 Earnings Snapshot - MySA
CytomX Therapeutics Inc earnings beat by $0.21, revenue topped estimates - Investing.com South Africa
Transcript : CytomX Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Latham & Watkins Advises CytomX Therapeutics on US$100 Million Underwritten Offering of Common Stock - Latham & Watkins LLP
CytomX Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
CytomX Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CTMX) - Seeking Alpha
CytomX shares priced at $1.30 in $100 million offering By Investing.com - Investing.com South Africa
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report - Benzinga
CytomX Shares Jump After Q1 Beat, 'Positive' Interim Trial Data - marketscreener.com
Earnings call transcript: CytomX Therapeutics Q1 2025 earnings beat expectations - Investing.com
Earnings call transcript: CytomX Therapeutics Q1 2025 earnings beat expectations By Investing.com - Investing.com India
CytomX Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CytomX Therapeutics shares soar on positive cancer drug data By Investing.com - Investing.com South Africa
CytomX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
CytomX Therapeutics shares soar on positive cancer drug data - Investing.com Australia
CytomX Therapeutics Inc (CTMX) Q1 2025 Earnings: Revenue Surges to $50.9 Million, Beating Estimates - GuruFocus
CytomX Therapeutics (CTMX) Rises on $100M Offering and Positive Study Results - GuruFocus
Is CytomX Therapeutics Inc (NASDAQ: CTMX) A Great Stock To Invest In? - Stocksregister
Cytomx Announces Positive Interim Data From Phase 1 Dose Escalation Study Of Epcam Antibody Drug Conjugate (Cx-2051) Candidate In Patients With Advanced Colorectal Cancer (Crc) - marketscreener.com
CytomX Therapeutics reports Q1 EPS 27c, consensus 13c - TipRanks
CytomX Therapeutics Announces Pricing of $100 Million Underwritt - GuruFocus
CytomX Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus
CytomX shares priced at $1.30 in $100 million offering - Investing.com Australia
CytomX Announces Positive Interim Data From Phase 1 Dose Escalat - GuruFocus
CytomX Therapeutics (CTMX) Reports Promising Phase 1 Results for CX-2051 in CRC | CTMX Stock News - GuruFocus
CytomX (CTMX) Surpasses Earnings and Revenue Expectations - GuruFocus
CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering (CTMX:NASDAQ) - Seeking Alpha
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - The Manila Times
CytomX Therapeutics Reports Positive Interim Phase 1 Data - TipRanks
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytomx Therapeutics Inc 주식 (CTMX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ogden Christopher | Chief Financial Officer |
Mar 18 '25 |
Sale |
0.60 |
8,551 |
5,122 |
201,026 |
| Chu Yu-Waye | Chief Medical Officer |
Mar 18 '25 |
Sale |
0.60 |
4,025 |
2,411 |
135,725 |
| ROWLAND LLOYD A | General Counsel |
Mar 18 '25 |
Sale |
0.60 |
10,203 |
6,112 |
120,594 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Mar 18 '25 |
Sale |
0.60 |
19,512 |
11,688 |
248,636 |
| Landau Jeffrey B | Chief Business Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
123,237 |
| Landau Jeffrey B | Chief Business Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
119,056 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
179,829 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
175,648 |
| ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
134,978 |
| ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
130,797 |
1.54%
7.58%
자본화:
|
볼륨(24시간):